The Details:
NGM Biopharmaceuticals confirmed the receipt of the EOI dated Dec. 28 and stated that the company has formed a special committee consisting of disinterested and independent directors to consider the EOI and any other strategic alternatives that may be available to the company.
NGM Price Action: According to Benzinga Pro, NGM Biopharmaceuticals shares are up 49% at $1.28 at the time of publication.
Image: Arek Socha from Pixabay
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
